BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones
August 12, 2016 6:29 AM EDT
Maxim Group downgraded BioLineRx (NASDAQ: BLRX) from Buy to Hold with a price target of $1.00 (from $4.00).
Analyst Jason Kolbert highlighted:
The biotechnology bear market that emerged in 2015 continues to drive an increase in the cost of capital and the dilution that companies face. The net result has been a shift in valuations, particularly for microcap companies, to the low end of the...
More
August 11, 2016 11:46 AM EDT
Roth Capital affirms BioLineRx (Nasdaq: BLRX) at Buy with a price target of $7 following Q2 results and appointment of a new CEO, as announced early Thursday.
Analyst Joseph Pantginis commented, The company has several important catalysts slated by year-end, which should be able to address the recent... More
August 11, 2016 6:47 AM EDT
BioLineRx Ltd. (Nasdaq: BLRX) announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016.
Mr. Serlin joined the Company in 2009 as its Chief Financial and Operating Officer. He succeeds Kinneret Savitsky, Ph.D., who joined the Company in 2004, and has served as its Chief Executive Officer since 2010. Dr. Savitsky will serve as scientific advisor to the Company through the end of March 2017.
"On behalf of the Board, I would like to thank Kinneret Savitsky for her outstanding leadership and many... More
